Follow-on offerings raised a total of $525 million for Amicus Therapeutics, Alder BioPharmaceuticals and Arena Pharmaceuticals. Amicus is on its way to submit a new-drug application for Fabry's disease drug migalastat, while Arena's pulmonary arterial hypertension drug ralinepag has met its primary endpoint in a midstage study.
Amicus, Alder, Arena raise total of $525M in follow-on offerings
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.